Robin K. Meray tests compounds at Link, which is developing a drug for Alzheimer's and Parkinson's.
(Suzanne Kreiter/Globe Staff)
Cambridge biotech raises $40m to test Alzheimer's drug
Bay State firms increasingly rely on venture backing
Robin K. Meray tests compounds at Link, which is developing a drug for Alzheimer's and Parkinson's.
(Suzanne Kreiter/Globe Staff)
Despite turmoil in financial markets, venture capital hasn't completely dried up for the region's promising technology and biotechnology companies. (Full article: 443 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
